Trial Profile
Human Immune Responses to an Adjuvanted H5 Vaccine: Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Mar 2020
Price :
$35
*
At a glance
- Drugs GSK 2321138A (Primary) ; AS03A
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics
- 01 Feb 2020 Status changed from active, no longer recruiting to completed.
- 28 Aug 2019 Planned primary completion date changed from 30 May 2019 to 1 Jan 2020.
- 28 Aug 2019 Status changed from recruiting to active, no longer recruiting.